Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples

Inflammatory Bowel Diseases

Volumn 22, Issue 4, 2016, Pages 969-975

  Gils, Ann ^a   Van Stappen, Thomas ^a   Dreesen, Erwin ^a   Storme, Ruth ^a   Vermeire, Séverine ^b   Declerck, Paul J ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

anti drug antibody; biosimilar pharmaceuticals; CT P13; infliximab; therapeutic drug monitoring

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOSIMILAR AGENT; CORTICOSTEROID; DRUG ANTIBODY; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; GASTROINTESTINAL AGENT;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; ULCERATIVE COLITIS; ADOLESCENT; AGED; ANIMAL; BIOASSAY; BLOOD; COLITIS, ULCERATIVE; COMPARATIVE STUDY; DOSE RESPONSE; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; MOUSE; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; BIOSIMILAR PHARMACEUTICALS; COLITIS, ULCERATIVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE; MICE; MIDDLE AGED; YOUNG ADULT;

EID: 84962299660     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000709     Document Type: Article

References (32)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
3. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-Tumor necrosis factor alpha monoclonal antibody combined with low-Dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
4. Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti-TNF-Alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology. 2005;44:670-676.
5. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-To-severe psoriasis: a phase III, multicentre, doubleblind trial. Lancet. 2005;366:1367-1374.
6. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523-529.
7. Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20: 2247-2259.
8. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721-1727.
9. Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147:1296-1307.e1295.
10. Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict longterm outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:531-538.
11. Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16:378.
12. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320-1329.
13. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698.
14. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355-366.
15. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-Analysis. Am J Gastroenterol. 2013;108: 40-47.
16. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-Term efficacy of infliximab in Crohns disease. N Engl J Med. 2003; 348:601-608.
17. Van Stappen T, Brouwers E, Tops S, et al. Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays. Ther Drug Monit. 2015;37:479-485.
18. Van Stappen T, Billiet T, Vande Casteele N, et al. An optimized antiinfliximab bridging enzyme-linked immunosorbent assay for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:2172-2177.
19. Danese S, Gomollon F; ECCO GBaOBo. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7:586-589.
20. Danese S, Gomollon F, Michetti P. EMA response to ECCO position statement on biosimilars. J Crohns Colitis. 2014;8:259.
21. European Medicines Agency: Remsima. European Public Assessment Report. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-Assessment-report/human/002576/WC500151486. pdf. Accessed July 23, 2015.
22. I European Medicines Agency: Inflectra. European Public Assessment Report. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-The-public/human/002778/WC500151491. pdf. Accessed July 23, 2015.
23. Declerck PJ. Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther. 2013;13:153-156.
24. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605-1612.
25. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallelgroup study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613-1620.
26. Xu Z, Seitz K, Fasanmade A, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol. 2008; 48:681-695.
27. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65:1211-1228.
28. Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohns disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33: 946-964.
29. Kang YS, Moon HH, Lee SE, et al. Clinical experience of the use of CTP13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60:951-956.
30. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30:1705-1712.
31. Steenholdt C, Brynskov J, Thomsen O, et al. Individualized therapy is a longterm cost-Effective method compared to dose intensification in Crohns disease patients failing infliximab. Dig Dis Sci. 2015;60:2762-2770.
32. Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab in remicade-Treated patients with IBD similarly recognise the biosimilar remsima. Gut. [published online ahead of print April 20, 2015]. doi: 10.1136/gutjnl-2015-309290.